Compare Charles River Laboratories Intl. Inc (CRL) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Nvidia Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Nvidia Corp trades at $233.7 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 391.4× Charles River Laboratories Intl. Inc's market cap, and Nvidia Corp pays a 0.43% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Nvidia Corp for 115 Days on average.
| CRL | NVDA | |
|---|---|---|
Market Cap | $14.23B | $5.57T |
Volume | 1,176,885 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $310.77 | $239.27 |
52-Week Low | $149.93 | $165.17 |
Typical Hold Time | 33 Days | 115 Days |
Enterprise Value | $17.06B | $5.54T |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid a broader tech sector rotation. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 55.84% net income margin and consistent earnings beats. Revenue growth accelerated to $130.50 billion in 2025, with analyst consensus remaining overwhelmingly positive.
The outlook for NVDA is favorable, driven by sustained AI chip demand and a $339.17 average price target implying significant upside. Key risks include heightened competition, market volatility from geopolitical tensions, and the stock's premium valuation. Long-term growth prospects remain robust, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
